• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.69% Nasdaq Up0.44%

    More On OXB.L

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Oxford BioMedica PLC (OXB.L)

    -LSE
    9.59 Up 0.01(0.08%) 6:28AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Oxford BioMedica PLC
    Windrush Court
    Transport Way
    Oxford, OX4 6LT
    United Kingdom - Map
    Phone: 44 1865 783000
    Fax: 44 1865 783001
    Website: http://www.oxfordbiomedica.co.uk

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:134

    Business Summary 

    Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing RetinoStat that has completed Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease and OXB-102 that is in Phase I/II trials preparation for the treatment of Parkinson's disease; and MoNuDin, which is in pre-clinical stage for the treatment of motor neuron disease. In addition, the company is developing TroVax that is in Phase II trial for colorectal cancer, ovarian cancer, and mesothelioma; Anti-5T4 antibody, which is in Phase I trial for the treatment of cancer; and CAR-T 5T4, a combination of LentiVector and 5T4 platform. It has collaborations with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb, and Immune Design Corp. Oxford BioMedica plc was founded in 1995 and is based in Oxford, the United Kingdom.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Oxford BioMedica PLC

    Key Executives 
     PayExercised
    Mr. John Dawson , 55
    Chief Exec. Officer and Exec. Director
    N/AN/A
    Mr. Timothy William Watts , 57
    Chief Financial Officer, Company Sec. and Exec. Director
    425.00KN/A
    Dr. Paul Blake M.D., 67
    Chief Devel. Officer, Exec. Director, Chairman of Remuneration Committee and Member of Nomination Committee
    177.00KN/A
    Mr. Peter Nolan , 62
    Chief Bus. Officer and Exec. Director
    N/AN/A
    Lara Mott ,
    Head of Corp. Communications
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in GBp.